A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

Mylan NV is poised to lose its hostile bid for Perrigo Co., people familiar with the matter said, a rare outcome in one of the bitterest takeover battles in decades.

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

When Mylan acquired EpiPen in 2007, the total market for epinephrine was around $207 million a year according to IMS Health. Even then, EpiPen was dominant, with its products accounting for nearly ...

Mylan also said it would offer a $25 discount on the co-pays for buyers with health insurance, and a savings card good for a discount of up to $300 on deductible or co-pay expenses for the branded ...

Mylan Inc., based in suburban Pittsburgh, became Netherlands-based Mylan N.V. last year to reduce its U.S. income taxes. But when you take a close look at Mylan’s business, it depends heavily on ...

Mylan NV, whose price increases on its lifesaving EpiPen drug drew broad criticism this month, said Monday it would launch a half-priced generic version of the medicine—in effect, competing ...